Cue Biopharma, Inc. Logo

Cue Biopharma, Inc.

Develops injectable biologics to selectively activate T cells for oncology & autoimmune disease.

CUE | US

Overview

Corporate Details

ISIN(s):
US22978P1066
LEI:
Country:
United States of America
Address:
40 GUEST STREET, 2135 BOSTON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company that develops a novel class of injectable biologics to selectively engage and modulate disease-specific T cells. The company's proprietary Immuno-STAT™ (Selective Targeting and Alteration of T cells) platform engineers therapeutics designed to mimic natural immune signals. This approach aims to selectively expand and activate specific immune cells directly within the patient's body, mobilizing the immune system to treat serious diseases. Cue Biopharma's pipeline focuses on developing precision immunotherapies for oncology and autoimmune and inflammatory diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Cue Biopharma, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cue Biopharma, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cue Biopharma, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Nuvation Bio Inc. Logo
A clinical-stage biopharma developing novel drugs for difficult-to-treat cancers.
United States of America NUVB
Nxera Pharma Co., Ltd. Logo
Biopharma using SBDD tech to develop medicines for neurology and gastroenterology.
Japan 4565
ObsEva SA Logo
Developed novel therapeutics for women's reproductive health and pregnancy.
Switzerland OBSN
OCULAR THERAPEUTIX, INC Logo
Develops hydrogel drug delivery therapies for eye diseases like wet AMD and glaucoma.
United States of America OCUL
Oculis Holding AG Logo
Clinical-stage biopharma developing non-invasive topical therapies for ophthalmic diseases.
United States of America OCS
ODI Pharma AB Logo
Distributes pharmaceutical medicinal cannabis products across Eastern Europe, with a focus on Poland.
Sweden ODI
Olema Pharmaceuticals, Inc. Logo
A clinical-stage biopharma developing targeted therapies for women's cancers, focusing on breast cancer.
United States of America OLMA
OliX Pharmaceuticals, Inc. Logo
Developing RNAi therapeutics for dermatology, ophthalmology, and metabolic diseases via an asiRNA platform.
South Korea 226950
OMEROS CORP Logo
Develops first-in-class therapeutics for challenging diseases with unmet medical needs.
United States of America OMER
ONCODESIGN Logo
Developing precision oncology solutions for resistant and metastatic cancers.
France ALONC

Talk to a Data Expert

Have a question? We'll get back to you promptly.